全文获取类型
收费全文 | 10153篇 |
免费 | 821篇 |
国内免费 | 424篇 |
专业分类
耳鼻咽喉 | 50篇 |
儿科学 | 229篇 |
妇产科学 | 175篇 |
基础医学 | 1769篇 |
口腔科学 | 210篇 |
临床医学 | 753篇 |
内科学 | 2258篇 |
皮肤病学 | 130篇 |
神经病学 | 911篇 |
特种医学 | 147篇 |
外国民族医学 | 1篇 |
外科学 | 829篇 |
综合类 | 998篇 |
现状与发展 | 1篇 |
预防医学 | 296篇 |
眼科学 | 148篇 |
药学 | 1885篇 |
4篇 | |
中国医学 | 169篇 |
肿瘤学 | 435篇 |
出版年
2023年 | 76篇 |
2022年 | 135篇 |
2021年 | 188篇 |
2020年 | 242篇 |
2019年 | 233篇 |
2018年 | 258篇 |
2017年 | 291篇 |
2016年 | 337篇 |
2015年 | 321篇 |
2014年 | 525篇 |
2013年 | 743篇 |
2012年 | 468篇 |
2011年 | 559篇 |
2010年 | 426篇 |
2009年 | 426篇 |
2008年 | 472篇 |
2007年 | 391篇 |
2006年 | 390篇 |
2005年 | 421篇 |
2004年 | 495篇 |
2003年 | 414篇 |
2002年 | 268篇 |
2001年 | 272篇 |
2000年 | 194篇 |
1999年 | 178篇 |
1998年 | 145篇 |
1997年 | 148篇 |
1996年 | 156篇 |
1995年 | 205篇 |
1994年 | 191篇 |
1993年 | 180篇 |
1992年 | 163篇 |
1991年 | 171篇 |
1990年 | 120篇 |
1989年 | 124篇 |
1988年 | 110篇 |
1987年 | 112篇 |
1986年 | 107篇 |
1985年 | 109篇 |
1984年 | 82篇 |
1983年 | 47篇 |
1982年 | 71篇 |
1981年 | 63篇 |
1980年 | 59篇 |
1979年 | 45篇 |
1978年 | 48篇 |
1977年 | 37篇 |
1976年 | 44篇 |
1974年 | 21篇 |
1973年 | 22篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
《Anaesthesia and Intensive Care Medicine》2020,21(11):572-577
Phaeochromocytomas and paragangliomas (PPGL) are catecholamine-secreting neuroendocrine tumours. These tumours may be identified incidentally, as part of a work-up for multiple endocrine neoplasia or following haemodynamic surges during unrelated procedures. Advances in preoperative management and improved management of intraoperative haemodynamic instability have significantly reduced surgical mortality from around 40% to less than 3%. Surgery is the definitive treatment in most cases and laparoscopic resection where possible is associated with improved outcomes. Anaesthetic management of PPGL cases represents a unique haemodynamic challenge both before, during and after tumour resection. In this article we describe the physiology of these tumours, their diagnosis, preoperative optimization methods, intraoperative anaesthetic management and management of postoperative complications. 相似文献
2.
Alexandra Katsimardou Konstantinos Imprialos Konstantinos Stavropoulos Alexandros Sachinidis Michalis Doumas 《Expert opinion on pharmacotherapy》2020,21(10):1241-1252
ABSTRACT
Introduction
Type 1 diabetes mellitus (T1DM) is a chronic, autoimmune disease that is characterized by total absence of insulin production. Hypertension is a common comorbidity in T1DM with complex pathophysiology, while it is also a well-recognized risk factor for the development of cardiovascular disease (CVD), as well as other microvascular diabetic complications. 相似文献3.
Alessandro Vatrella Angelantonio Maglio Corrado Pelaia Girolamo Pelaia Carolina Vitale 《Expert opinion on pharmacotherapy》2020,21(12):1505-1515
ABSTRACT
Introduction
‘Critical Asthma Syndrome’ (CAS) is an umbrella term proposed to include several forms of asthma, responsible for acute and life-threatening exacerbations. CAS requires urgent and adequate supportive and pharmacological treatments to prevent serious outcomes. 相似文献4.
5.
6.
Wilbert S Aronow 《Expert opinion on pharmacotherapy》2016,17(2):205-215
Introduction: It is important to know how to treat hypertension in patients with coronary artery disease (CAD). The reason for the review was to update this treatment and to discuss the 2015 American Heart Association/American College of Cardiology/American Society of Hypertension 2015 guidelines of treatment of hypertension in patients with CAD.Areas covered: Studies between 1968 and 2015 were reviewed on treatment of hypertension in patients with CAD using a Medline search, and studies between 1977 and 2015 were reported. Hypertension should be treated with beta blockers and ACE inhibitors or angiotensin receptor blockers (ARBs). Long-acting nitrates are effective antianginal and anti-ischemic drugs. Calcium-channel blockers (CCBs) may be added if angina persists despite beta blockers and long-acting nitrates. The 2015 guidelines recommend that the blood pressure should be < 140/90 mm Hg in patients aged ≤ 80 years and the systolic blood pressure < 150 mm Hg if they are ≥ 80 years.Expert opinion: Hypertension in patients with CAD should be treated with beta blockers and ACE inhibitors or ARBs. Long-acting nitrates are effective antianginal and anti-ischemic drugs. CCBs may be added if angina persists despite beta blockers and long-acting nitrates. The blood pressure should be < 140/90 mm Hg in patients aged < 80 years and the systolic blood pressure < 150 mm Hg if they are ≥ 80 years. 相似文献
7.
Thaís dos Santos Fontes Pereira Carolina Cavalieri Gomes Peter A Brennan Felipe Paiva Fonseca Ricardo Santiago Gomez 《Journal of oral pathology & medicine》2019,48(1):3-9
Fibrous dysplasia is a non‐neoplastic developmental process that affects the craniofacial bones, characterized by painless enlargement as a result of bone substitution by abnormal fibrous tissue. Postzygotic somatic activating mutations in the GNAS1 gene cause fibrous dysplasia and have been extensively investigated, as well as being helpful in the differential diagnosis of the disease. Fibrous dysplasia may involve one (monostotic) or multiple bones (polyostotic), sporadically or in association with McCune‐Albright syndrome, Jeffe‐Lichenstein syndrome, or Mazabreud syndrome. This review summarizes the current knowledge on fibrous dysplasia, emphasizing the value of integrating the understanding of its molecular pathogenesis with the clinical, radiological, and histopathological features. In addition, we address important aspects related to the differential diagnosis and patient management. 相似文献
8.
目的探讨补骨脂素抗增生性瘢痕的作用机制。方法体外培养成纤维细胞,按随机数字表法分为正常组(培养正常成纤维细胞)、瘢痕组(培养增生性瘢痕成纤维细胞)、TGF-β1组(10 ng/ml TGF-β1处理增生性瘢痕成纤维细胞5 min^12 h)、Smurf2 RNA干扰组[Smad泛素化调节因子2(Smad ubiquitin regulatory factor2,Smurf2)siRNA转染增生性瘢痕成纤维细胞72 h]、补骨脂素组(10μmol/L补骨脂素处理增生性瘢痕成纤维细胞继续培养72 h)、补骨脂素+TGF-β1组(增生性瘢痕成纤维细胞加入补骨脂素培养72 h后加入TGF-β1培养6 h)。采用Western blot法检测Smurf2、α-平滑肌肌动蛋白(α-actin SMA,α-SMA)蛋白表达;RT-PCR法检测Ⅰ型胶原蛋白mRNA表达;ELISA法检测TGF-β1蛋白分泌。结果与正常组比较,瘢痕组Smurf2蛋白[(0.83±0.08)比(0.38±0.07)]表达增加(P<0.05);与瘢痕组比较,Smurf2 RNA干扰组TGF-β1[(2.2±0.18)比(4.2±0.47)]表达降低(P<0.05);TGF-β1组Smurf2[(0.71±0.06)比(0.42±0.04)]、α-SMA[(1.42±0.12)比(0.91±0.09)]蛋白表达增加(P<0.05),Ⅰ型胶原蛋白mRNA[(0.72±0.09)比(0.41±0.07)]表达增加(P<0.05);补骨脂素组Smurf2[(0.05±0.01)比(0.42±0.04)]、α-SMA[(0.71±0.07)比(0.91±0.09)]蛋白表达降低(P<0.05),Ⅰ型胶原蛋白mRNA表达[(0.12±0.04)比(0.41±0.07)]降低(P<0.05)。结论补骨脂素可能通过TGF-β1/Smurf2信号通路抑制α-SMA蛋白表达,从而降低Ⅰ型胶原蛋白表达,起到抑制瘢痕形成的作用。 相似文献
9.
Antony E. Shrimpton Robert L. Schelper Reinhold P. Linke John Hardy Richard Crook Dennis W. Dickson Takashi Ishizawa Richard L. Davis 《Neuropathology》2007,27(3):228-232
Over 100 mutations in the presenilin‐1 gene (PSEN1) have been shown to result in familial early onset Alzheimer disease (EOAD), but only a relatively few give rise to plaques with an appearance like cotton wool (CWP) and/or spastic paraparesis (SP). A family with EOAD, seizures and CWP was investigated by neuropathological study and DNA sequencing of the PSEN1 gene. Aβ was identified in leptomeningeal vessels and in cerebral plaques. A single point mutation, p.L420R (g.1508T > G) that gives rise to a missense mutation in the eighth transmembrane (TM8) domain of PS1 was identified in two affected members of the family. p.L420R (g.1508T > G) is the mutation responsible for EOAD, seizures and CWP without SP in this family. 相似文献
10.
用放射配体结合分析法分别测定了正常组、特布他林组、特布他林十曲尼司特组豚鼠的肺组织β受体最大结合力和解离常数,结果显示:给特布他林后豚鼠肺组织β受体发生明显的向下调节.曲尼司特可预防此向下调节的发生. 相似文献